{"filing":{"accession_number":"0001867096-26-000063","cik":"0001867096","ticker":"XERS","company_name":"Xeris Biopharma Holdings, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"xers-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000063/xers-20260806.htm"},"events":[{"id":25999,"run_id":23610,"accession_number":"0001867096-26-000063","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Xeris Biopharma issued a press release on August 6, 2026, disclosing financial results for the second quarter and six months ended June 30, 2026. The filing explicitly states in Item 2.02 that the Company \"issued a press release containing information about the Company's results of operations and business highlights\" and furnishes the press release as Exhibit 99.1. The exhibit contains detailed quarterly and year-to-date financial results including revenue ($92.1M Q2, $175.2M YTD), product-specific revenue breakdowns, gross margin, operating expenses, net loss, and Adjusted EBITDA, along with forward-looking guidance tightening full-year 2026 revenue to $385–$390 million. This is a standard earnings release disclosure under Item 2.02.","company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26970,"accession_number":"0001867096-26-000063","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Xeris Biopharma issued a press release on August 6, 2026, disclosing financial results for the second quarter and six months ended June 30, 2026. The filing explicitly states in Item 2.02 that the Company \"issued a press release containing information about the Company's results of operations and business highlights\" and furnishes the press release as Exhibit 99.1. The exhibit contains detailed quarterly and year-to-date financial results including revenue ($92.1M Q2, $175.2M YTD), product-specific revenue breakdowns, gross margin, operating expenses, net loss, and Adjusted EBITDA, along with forward-looking guidance tightening full-year 2026 revenue to $385–$390 million. This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:54:05.573572+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26970,"accession_number":"0001867096-26-000063","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Xeris Biopharma issued a press release on August 6, 2026, disclosing financial results for the second quarter and six months ended June 30, 2026. The filing explicitly states in Item 2.02 that the Company \"issued a press release containing information about the Company's results of operations and business highlights\" and furnishes the press release as Exhibit 99.1. The exhibit contains detailed quarterly and year-to-date financial results including revenue ($92.1M Q2, $175.2M YTD), product-specific revenue breakdowns, gross margin, operating expenses, net loss, and Adjusted EBITDA, along with forward-looking guidance tightening full-year 2026 revenue to $385–$390 million. This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:54:05.573572+00:00","company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","filing_date":"2026-08-06"}]}